For Qiagen, Innovation and Execution to Drive Above-Market Growth
Qiagen is a leading player in the life sciences industry, with core strengths in sample preparation and analytics, and additional activities in clinical diagnostics.
Qiagen NV QGEN
Bulls Say, Bears Say
Bulls
Qiagen is active in multiple potentially fast-growing end markets like dPCR and bioinformatics, and has product launches coming up, supporting strong growth over the long run.
Bears
Qiagen will continue to face intense competition in its heavily invested diagnostics markets, which could potentially harm the company’s financial returns.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
-
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
-
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
-
Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky
-
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
-
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
Trading Information
- Previous Close Price
- $37.56
- Day Range
- $36.54–37.81
- 52-Week Range
- $32.53–57.82
- Bid/Ask
- $34.00 / $45.00
- Shares Outstanding
- 206.25M
- Market Cap
- $7.57B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 15.07
- Price/Sales
- 3.58
- Dividend Yield (Trailing)
- 0.72%
- Dividend Yield (Forward)
- 0.95%
- Total Yield
- 8.28%
Company Profile
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 5,500
- Website
- https://www.qiagen.com
Competitors
Valuation
|
Metric
|
QGEN
|
TMO
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.07 | 20.41 | 23.10 |
Price/Book Value | 2.27 | 3.38 | 2.46 |
Price/Sales | 3.58 | 3.94 | 5.31 |
Price/Cash Flow | 11.11 | 18.27 | 18.21 |
Price/Earnings
QGEN
TMO
DHR
Financial Strength
|
Metric
|
QGEN
|
TMO
|
DHR
|
|---|---|---|---|
Quick Ratio | 2.18 | 0.97 | 1.28 |
Current Ratio | 3.21 | 1.53 | 1.87 |
Interest Coverage | 11.73 | 5.35 | 17.75 |
Quick Ratio
QGEN
TMO
DHR
Profitability
|
Metric
|
QGEN
|
TMO
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 8.54% | 8.27% | 5.62% |
Return on Equity (Normalized) | 14.48% | 17.01% | 8.81% |
Return on Invested Capital (Normalized) | 9.42% | 10.28% | 6.81% |
Return on Assets
QGEN
TMO
DHR
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Vqwwkycdsp | Zpm | $176B | |||
| Danaher Corp
DHR
| Txgzjhvcsk | Rbjq | $130B | |||
| IDEXX Laboratories Inc
IDXX
| Zchyvhctz | Frfb | $44B | |||
| Agilent Technologies Inc
A
| Hrmhfkjgb | Tqmg | $38B | |||
| Waters Corp
WAT
| Ltgsspltz | Kwcx | $36B | |||
| IQVIA Holdings Inc
IQV
| Pybxlrbg | Lvnhmj | $31B | |||
| Illumina Inc
ILMN
| Wvxtztrfp | Fzbywv | $25B | |||
| Mettler-Toledo International Inc
MTD
| Wfmkyttwb | Hxzlcnd | $23B | |||
| Quest Diagnostics Inc
DGX
| Xsydsqtw | Lqytnn | $22B | |||
| Labcorp Holdings Inc
LH
| Ddrhgbkcx | Pcthgs | $22B |
United States